Anti-platelet and anti-thrombosis characteristics of Z4A5, a novel selective platelet glycoprotein IIb/IIIa inhibitor, compared with eptifibatide under long-term infusion

Author： Shi X.L.   Shen S.   Guo M.M.   Zhang G.J.   Che J.   Wang B.   Zhou J.  

Publisher： Govi-Verlag

ISSN： 0031-7144

Source： Die Pharmazie - An International Journal of Pharmaceutical Sciences, Vol.70, Iss.12, 2015-12, pp. : 810-814

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Eptifibatide: a potent inhibitor of the platelet receptor integrin glycoprotein IIb/IIIa

By Tcheng James E   O’Shea J Conor  

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 8, 2002-08 ,pp. : 1199-1210

Informa Healthcare

Access to resources Recommend Favorite

Effects Of Glycoprotein IIb/IIIa Antagonists: Anti Platelet Aggregation And Beyond

By  

Current Drug Metabolism, Vol. 17, Iss. 2, 2016-02 ,pp. : 194-203

Bentham Science Publishers

Access to resources Recommend Favorite

The Role of the Platelet Glycoprotein IIb / IIIa in Thrombosis and Haemostasis

By  

Current Pharmaceutical Design, Vol. 10, Iss. 14, 2004-05 ,pp. : 1567-1576

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacological properties of YM-57029, a novel platelet glycoprotein IIb/IIIa antagonist

By Moritani Y.   Sato K.   Shigenaga T.   Hisamichi N.   Ichihara M.   Akamatsu S.   Suzuki K.-i.   Nii T.   Kaku S.   Kawasaki T.   Matsumoto Y.   Inagaki O.   Tomioka K.   Yanagisawa I.  

European Journal of Pharmacology, Vol. 439, Iss. 1, 2002-03 ,pp. : 43-52

Elsevier

Access to resources Recommend Favorite

Platelet Glycoprotein IIb/IIIa Inhibitors in Percutaneous Coronary Intervention: Focus on the Pharmacokinetic-Pharmacodynamic Relationships of Eptifibatide

By Gilchrist I.C.  

Clinical Pharmacokinetics, Vol. 42, Iss. 8, 2003-01 ,pp. : 703-720

Adis International

Access to resources Recommend Favorite